Substance delivery device and substance delivery method using the same

專利類型

發明

專利國別 (專利申請國家)

美國

專利申請案號

14/328,571

專利證號

US 10,028,905 B2

專利獲證名稱

Substance delivery device and substance delivery method using the same

專利所屬機關 (申請機關)

國立成功大學

獲證日期

2018/07/24

技術說明

本研究以幾丁聚醣微針和水溶式高分子貼片組合而成，製備出一微針可鑲嵌式之經皮貼片系統。此微針貼片能在穿刺皮膚後，藉由體內組織液將後端支撐貼片溶解，使前端幾丁聚醣針體留在皮膚中，緩慢而持續地釋放藥物，讓藥效更加持久。 本研究利用幾丁聚醣微針包覆疫苗，製備出一經皮緩釋疫苗之新型微針貼片，微針的穿刺成功率可達100%，穿刺深度約為600 μm，能成功刺穿皮膚角質層到達有大量抗原呈現細胞存在的表皮層與真皮層。實驗證實，幾丁聚醣微針確實可長效釋放所包覆的抗原至少三週，確認其緩釋疫苗之能力。利用幾丁聚醣微針經皮傳輸抗原，可誘發較傳統肌肉注射更強的抗體反應，且持續至少六週，預期此新型之微針系統，將有潛力取代傳統注射型疫苗，提供一更無痛、方便且有效之經皮免疫方式。此緩釋型微針貼片，可減少病患之施藥次數並增加用藥之便利性，避免貼片長時間黏貼於皮膚所造成之不適。本研究擬開發之鑲嵌式微針，主要由生物可降解的幾丁聚醣所製成，整支針皆可包覆藥物，包藥量可大為提升，製程溫和且量產容易，未來可應擴大應於經皮長效傳輸各種蛋白質藥物。 This study introduces a microneedle transdermal delivery system, composed of embeddable chitosan microneedles and a dissolving supporting array, for complete and sustained delivery of encapsulated antigens to the skin. When inserted into rat skin in vivo, chitosan microneedles successfully separated from the supporting array and were left within the skin for sustained drug delivery without requiring a transdermal patch. To evaluate the utility of chitosan microneedles for intradermal vaccination, ovalbumin (OVA; MW = 44.3 kDa) was used as a model antigen. When the OVA-loaded microneedles were embedded in rat skin in vivo, histological examination showed that the microneedles gradually degraded and prolonged OVA exposure at the insertion sites for up to 21 days. Compared to traditional intramuscular immunization, rats immunized by a single microneedle dose of OVA showed a significantly higher OVA-specific antibody response which lasted for at least 6 weeks.

備註

連絡單位 (專責單位/部門名稱)

企業關係與技轉中心

連絡電話

06-2360524

網址